Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
- Autores
- Marin, Lupe; Blanco, Luis; Marin, Gina; Aguero, Sergio; Pagnotta, Mariana; Marin, Gustavo Horacio
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin.Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic eventsassociated to oral contraceptive use, we developed the present study.Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex,combination consumed, doses, co-morbidities, thrombotic events.Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel,gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (eitherdepth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generationoptions). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins whencompared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestindenote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies thatprovide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning.However, the combinations provided should not expose population to additional and unnecessary risks.
Fil: Marin, Lupe. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; Argentina
Fil: Blanco, Luis. No especifíca;
Fil: Marin, Gina. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; Argentina
Fil: Aguero, Sergio. No especifíca;
Fil: Pagnotta, Mariana. No especifíca;
Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina - Materia
-
CONTRACEPTIVES
THROMBOSIS
PROGESTIN
RISK - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/139291
Ver los metadatos del registro completo
id |
CONICETDig_c7092df4ba58b0bcce2ab850a9e3aee7 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/139291 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination usedMarin, LupeBlanco, LuisMarin, GinaAguero, SergioPagnotta, MarianaMarin, Gustavo HoracioCONTRACEPTIVESTHROMBOSISPROGESTINRISKhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin.Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic eventsassociated to oral contraceptive use, we developed the present study.Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex,combination consumed, doses, co-morbidities, thrombotic events.Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel,gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (eitherdepth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generationoptions). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins whencompared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestindenote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies thatprovide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning.However, the combinations provided should not expose population to additional and unnecessary risks.Fil: Marin, Lupe. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; ArgentinaFil: Blanco, Luis. No especifíca;Fil: Marin, Gina. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; ArgentinaFil: Aguero, Sergio. No especifíca;Fil: Pagnotta, Mariana. No especifíca;Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaSociety of Pharmaceutical Technocrats2020-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/139291Marin, Lupe; Blanco, Luis; Marin, Gina; Aguero, Sergio; Pagnotta, Mariana; et al.; Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used; Society of Pharmaceutical Technocrats; Journal of Drug Delivery and Therapeutics; 10; 5; 9-2020; 198-2012250-1177CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.22270/jddt.v10i5.4315info:eu-repo/semantics/altIdentifier/url/http://jddtonline.info/index.php/jddt/article/view/4315info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:25:21Zoai:ri.conicet.gov.ar:11336/139291instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:25:21.765CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used |
title |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used |
spellingShingle |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used Marin, Lupe CONTRACEPTIVES THROMBOSIS PROGESTIN RISK |
title_short |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used |
title_full |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used |
title_fullStr |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used |
title_full_unstemmed |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used |
title_sort |
Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used |
dc.creator.none.fl_str_mv |
Marin, Lupe Blanco, Luis Marin, Gina Aguero, Sergio Pagnotta, Mariana Marin, Gustavo Horacio |
author |
Marin, Lupe |
author_facet |
Marin, Lupe Blanco, Luis Marin, Gina Aguero, Sergio Pagnotta, Mariana Marin, Gustavo Horacio |
author_role |
author |
author2 |
Blanco, Luis Marin, Gina Aguero, Sergio Pagnotta, Mariana Marin, Gustavo Horacio |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
CONTRACEPTIVES THROMBOSIS PROGESTIN RISK |
topic |
CONTRACEPTIVES THROMBOSIS PROGESTIN RISK |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin.Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic eventsassociated to oral contraceptive use, we developed the present study.Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex,combination consumed, doses, co-morbidities, thrombotic events.Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel,gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (eitherdepth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generationoptions). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins whencompared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestindenote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies thatprovide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning.However, the combinations provided should not expose population to additional and unnecessary risks. Fil: Marin, Lupe. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; Argentina Fil: Blanco, Luis. No especifíca; Fil: Marin, Gina. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; Argentina Fil: Aguero, Sergio. No especifíca; Fil: Pagnotta, Mariana. No especifíca; Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina |
description |
Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin.Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic eventsassociated to oral contraceptive use, we developed the present study.Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex,combination consumed, doses, co-morbidities, thrombotic events.Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel,gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (eitherdepth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generationoptions). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins whencompared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestindenote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies thatprovide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning.However, the combinations provided should not expose population to additional and unnecessary risks. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/139291 Marin, Lupe; Blanco, Luis; Marin, Gina; Aguero, Sergio; Pagnotta, Mariana; et al.; Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used; Society of Pharmaceutical Technocrats; Journal of Drug Delivery and Therapeutics; 10; 5; 9-2020; 198-201 2250-1177 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/139291 |
identifier_str_mv |
Marin, Lupe; Blanco, Luis; Marin, Gina; Aguero, Sergio; Pagnotta, Mariana; et al.; Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used; Society of Pharmaceutical Technocrats; Journal of Drug Delivery and Therapeutics; 10; 5; 9-2020; 198-201 2250-1177 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.22270/jddt.v10i5.4315 info:eu-repo/semantics/altIdentifier/url/http://jddtonline.info/index.php/jddt/article/view/4315 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Society of Pharmaceutical Technocrats |
publisher.none.fl_str_mv |
Society of Pharmaceutical Technocrats |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614252165332992 |
score |
13.070432 |